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Negative immune regulatory pathways inhibit anti-cancer T cell responses, preventing effective immune
surveillance. Two clinical trials using monoclonal antibodies that antagonize the PD-1/PD-L1 pathway
recently reported regression in several tumor types. In one of these trials, efficacy was linked to the expres-
sion of the PD-L1 biomarker on tumor cells.Over the past few decades, we have often
heard in the halls of cancer meetings,
‘‘Immunotherapy is the future of cancer
treatment. and always will be.’’ The
idea that the immune system can be har-
nessed to destroy tumors has been
a dream for over a century, ever sinceWil-
liam Coley first injected toxins into
patients to treat cancer. Reporting in
a recent issue of New England Journal of
Medicine, Topalian et al. (2012) and
Brahmer et al. (2012) explore the clinical
effects of two complementary means of
achieving anti-tumor immunity in multiple
cancers including, for the first time, lung
cancer. These trials utilized monoclonal
antibodies (mAbs) targeting a cell surface
molecule programmed death-1 (PD-1) on
T cells and its ligand PD-L1, which is over-
expressed on cancer cells. The combina-
tion of these results and experiences with
ipilimumab, an FDA-approved mAb that
targets a related negative regulatory re-
ceptor cytotoxic T lymphocyte antigen 4
(CTLA-4), leaves no doubt that the future
is here, and with it, a new era in the treat-
ment of cancer.
The modern era of cancer immunology
has focused on using immunotherapy to
‘‘boost’’ the immune system through
vaccination and adoptive cellular immu-
notherapy based on the proposition that
tumors express antigenic protein targets,
but the anti-tumor T cells are not being
activated due to limited T cell activation,
growth factors, or immunosuppressive
molecules secreted by cancer cells them-
selves. In many instances, these efforts
have focused on promoting key positive
co-stimulatory and innate immune path-
ways (such as ICOS, CD28, CD154, andTLR ligands) that are critical for a potent
and sustained immune response. The
general thinking was that the immune
system was the lack of recognition and
induction of an anti-tumor response.
However, in the mid-90’s, it became clear
that the immune system did indeed
recognize tumor antigens (mostly overex-
pressed self proteins) but remained
quiescent in spite of the persistent pres-
ence of tumor antigens. This led to the
hypothesis that there must be an active
brake on the anti-tumor response that
shuts down active immunity. The break-
through came when it was discovered
that negative regulatory T cell surface
molecules (the first of which was
CTLA-4) were upregulated in activated
T cells to dampen their activity, resulting
in less effective killing of tumor cells
(Walunas et al., 1994, Leach et al.,
1996). These inhibitory molecules, termed
negative co-stimulatory molecules due to
their homology with the quintessential
T cell co-stimulatory molecule CD28,
included a number of related family
members including PD-1, B7-H4, B- and
T-lymphocyte attenuator (BTLA), and their
ligands (Bour-Jordan et al., 2011). The
molecules function by multiple pathways,
including the attenuation of early activa-
tion signals, competition for positive co-
stimulation, and direct inhibition of the
antigen presenting cells that would other-
wise promote immune responses. The
importance of these pathways was high-
lighted by studies showing that total
blockade via genetic disruption led to
massive T cell hyperproliferation and pro-
tracted multiorgan autoimmunity. Thus,
it became increasing clear that thereCancer Cwere a series of major pathways that the
immune system employs to avoid un-
wanted autoimmune or hyperimmune
responses. In various animal models,
administration of immune checkpoint
inhibitors (ICI) unleashed immunity to
tumors, viruses, and other pathogens.
These seminal studies ultimately led to
the development and FDA approval of
the first antibody-based immunotherapy
that targets negative co-stimulation ipili-
mumab (Yervoy) in patients with meta-
static melanoma (Hodi et al., 2010).
The first clinical trials of ICI-specific
mAbs against the receptor PD-1 and its
ligand PD-L1 included subjects with
late-stage, heavily-pretreated kidney,
lung, prostate, and colon cancer. They
took advantage of newly conceived adap-
tive trial designs to move rapidly from
a dose finding mode in multiple tumor
types to rapid efficacy expansion cohorts
(Wolchok et al., 2009). The data are quite
encouraging and go beyond typical
expectations. Overall, approximately
20%–25% of patients with metastatic
melanoma, kidney (renal cell) and lung
(non-small cell) cancer had partial or
complete tumor shrinkage. Importantly,
the durability of the responses was unpar-
alleled as 65% of patients followed for
greater than one year remained respon-
sive (Topalian et al., 2012; Brahmer
et al., 2012). The relatively low responses
of the lung cancer patients to the PD-1
pathway immunotherapy is an important
starting point for developing treatments
that couple the ICIs with other therapies.
While these trials were highlighted for
their success, it must be noted that the
inherent risk in approaches that harnessell 22, July 10, 2012 ª2012 Elsevier Inc. 7
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immunity is the development of autoim-
munity. While ipilimumab and these anti-
bodies have not been directly compared,
there appears to be less severe immune-
related toxicity with the anti-PD-1 and
anti-PD-L1 mAbs. Nevertheless, grade 3
and 4 toxicity did occur in 9% (Brahmer
et al., 2012) and 11% (Topalian et al.,
2012) of patients, and episodes of
presumed autoimmune pneumonitis, in-
cluding some with fatal outcomes, colitis,
hepatitis, hypophysitis, and thyroiditis
were noted. Importantly, autoimmunity
can usually be treated with immune
suppressive therapy without an apparent
effect on anti-cancer immunity. The
finding that the autoimmune side-effect
profile is different between the different
ICI drugs raises the question as to
whether this is due to more ‘‘down-
stream’’ and specific roles of the PD-1-
PD-L1 interaction in cancer.
It is important to note that the effect of
these drugs represents a growing class
effect, as demonstrated by the clinical
activity of ipilimumab in renal cell carci-
noma, prostate cancer, and melanoma.
In addition, inhibitors of other targets,
such as TIM-3, BTLA, etc., are working
their way through pre-clinical and clinical
development (Norde et al., 2012). As is
the case with ipilimumab, treatment with
anti-PD-1 and anti-PD-L1 mAbs did not
appear to benefit patients with prostate
or colon cancer. However, the responses
in melanoma and kidney cancer were
greater than that seen with ipilimumab.8 Cancer Cell 22, July 10, 2012 ª2012 ElseviThe reason for these differences remain
unclear, but it is important to note that
there appeared to be a correlation
between patient response and the
expression level of PD-L1 on the tumor
cells in the anti-PD-1 study (Topalian
et al., 2012). In preliminary results, 9 of
25 (36%) patients with PD-L1 positive
cancers had an objective response,
whereas none of the 17 patients whose
tumors were PD-L1 negative had an
objective response. The results suggest
that receptor-target localization may
define key differences in the efficacy of
these agents, as CTLA-4 ligands and
PD-1 ligands are differentially expressed
on hematopoietic cells versus stromal
cells, respectively. Moreover, the PD-1-
PD-L1 pathway preferentially controls
effector-memory CD8+ T cell responses
at the tissue site, while CTLA-4, via inter-
action with CD80 and CD86, has been
shown to control early T cell responses
in lymphoid tissues (Jin et al., 2011;
Egan et al., 2002). Finally, the use of ICIs
in combination with specific tumor and
tumor antigen immunization may prove
extremely effective in these therapeutic
settings to boost existing responses and
initiate de novo immunity.
In summary, these two studies provide
compelling evidence that immuno-
therapy is no longer the future of cancer
treatment, but is very much a current
reality. The articles by Brahmer et al.
(2012) and Topalian et al. (2012) provide
critical insights into how further under-
standing of the basis of cancer immu-er Inc.nology will lead to advances that benefit
our patients.REFERENCES
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